

Visit the web at:  
<http://novartis.medicalcongressposters.com/Default.aspx?doc=19b1c>  
 Copies of this presentation obtained through QR (Quick Response) code are for personal use only and may not be reproduced without written permission of the authors



Presenter email address:  
 Stanley.Cohan@providence.org

Scan this QR code

# Safety and Efficacy of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis Identifying as Hispanic from the EXPAND Study

Stanley Cohan<sup>1</sup>, Le H Hua<sup>2</sup>, Amit Bar-Or<sup>3</sup>, Fred D Lublin<sup>4</sup>, Xiangyi Meng<sup>5</sup>, Gina Mavrikis Cox<sup>5</sup>, Patricia K Coyle<sup>6</sup>, Robert J Fox<sup>7</sup>

<sup>1</sup>Providence Brain and Spine Institute, and Providence Multiple Sclerosis Center, Providence Health & Services, Portland, OR, USA; <sup>2</sup>Lou Ruvo Center for Brain Health, Las Vegas, NV, USA; <sup>3</sup>Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; <sup>4</sup>Icahn School of Medicine at Mount Sinai, New York, NY, USA; <sup>5</sup>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; <sup>6</sup>Multiple Sclerosis Comprehensive Care Center, Stony Brook University, Stony Brook, NY, USA; <sup>7</sup>Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.

## Background

- Over 50% of RRMS patients are expected to transition to SPMS within 15 to 20 years after disease onset<sup>1,2</sup>
- In SPMS, relapses are infrequent or absent, yet disability continues to gradually worsen<sup>3</sup>
  - Available DMTs for relapsing MS have shown limited potential to delay gradual disability accrual<sup>4</sup>
- Siponimod is an oral selective sphingosine 1-phosphate 1 and 5 receptor modulator<sup>5,6</sup>
- EXPAND was a placebo-controlled, Phase 3 study of siponimod in an ambulatory SPMS population<sup>7</sup>
  - Siponimod significantly reduced risk of 3-month and 6-month CDP by 31% and 37%, respectively, in patients with active SPMS versus placebo
- Minority groups are persistently underrepresented in clinical trials, resulting in limited data to inform decision-making for minority patients, presenting an urgent need for clinical evidence

## Objective

- In an exploratory post hoc analysis, the efficacy and safety profile of siponimod 2 mg daily was analyzed in a subgroup of patients with active SPMS from EXPAND who identified as Hispanic

## Methods

### Study design and patient population

- Post hoc analysis included data from patients who identified as Hispanic and had active SPMS and were randomized (2:1) to receive siponimod 2 mg or placebo in the core study
  - Active SPMS defined as having  $\geq 1$  relapse in the 2 years before Baseline and/or  $\geq 1$  T1 gadolinium-enhancing lesion at Baseline
- Proportional hazard and ANCOVA models were applied to the analyses of time to 3- and 6-month CDP (as per EDSS scores) and change in SDMT, respectively
- Number and percentage of patients with adverse events (AEs) were reported

### Study endpoints

- Primary endpoint:** 3- and 6-month CDP Risk
- Secondary endpoints:**
  - SDMT score
  - Safety (any AEs, SAEs, and AEs leading to discontinuation)

## Results

### Patient characteristics

- Of 1651 patients in the overall EXPAND population, 106 (6.4%) identified as Hispanic, of which 40 had active SPMS (siponimod [n=31], placebo [n=9])
- Demographics and baseline characteristics in the subgroup of Hispanic patients with active SPMS are presented in **Table 1**


### 3- and 6-month CDP Risk

- Siponimod showed a reduction of 42% in 3-month CDP risk and of 67% in 6-month CDP risk vs placebo (**Figure 1**)

**Table 1. Patient demographics and baseline characteristics in Hispanic patients with active SPMS**

	Siponimod N=31	Placebo N=9
Age, mean (SD), years	46.9 (7.8)	49.0 (7.3)
Female, n (%)	12 (38.7)	2 (22.2)
Race, n (%)		
Other	1 (61.3)	1 (11.1)
White	30 (96.8)	8 (88.9)
Duration since MS onset, mean (SD), years	14.9 (6.1)	16.5 (7.6)
Time since conversion to SPMS, mean (SD), years	3.6 (2.7)	1.9 (1.1)
EDSS score, mean (SD)	5.5 (1.1)	5.2 (1.1)
SDMT score (SD)	38.7 (13.5)	41.1 (12.3)
Patients with $\geq 1$ MS relapse in the last 2 years prior to Baseline, n (%)	23 (74.2)	8 (88.9)
Relapses in the last 2 years prior to Baseline, n (%)		
1	10 (32.3)	3 (33.3)
2-3	11 (35.5)	4 (44.4)
4-5	2 (6.5)	1 (11.1)
Patients with number of Gd <sup>+</sup> T1 lesions, n (%)		
0	18 (58.1)	6 (66.7)
$\geq 1$	11 (35.5)	3 (33.3)
T2 lesion volume, cm <sup>3</sup> , mean (SD)	16175.7 (14916.81)	16240.7 (9325.39)
Normalized brain volume, cm <sup>3</sup> , mean (SD)	1441.6 (99.8)	1383.1 (75.7)

**Figure 1. Time to 3- and 6-month CDP**



**Table 2. Incidence of adverse events**

Event	Siponimod N=31 n (%)	Placebo N=9 n (%)
<b>Any AE</b>	22 (71.0)	7 (77.8)
<b>Any SAE</b>	3 (9.7)	1 (11.1)
<b>Any AE leading to discontinuation</b>	1 (3.2)	0 (0.0)
<b>AEs of interest</b>		
Alanine aminotransferase increased	3 (9.7)	0 (0.0)
Depression	3 (9.7)	1 (11.1)
Bradycardia	2 (6.5)	0 (0.0)
Headache	2 (6.5)	3 (33.3)
Urinary tract infection	2 (6.5)	3 (33.3)
Gait disturbance	1 (3.2)	0 (0.0)
Multiple sclerosis	1 (3.2)	0 (0.0)
<b>SAEs of interest</b>		
Alanine aminotransferase increased	1 (3.2)	0 (0.0)
Ischemic stroke*	1 (3.2)	0 (0.0)
Suicidal behavior	1 (3.2)	0 (0.0)
Urinary tract infection	0 (0.0)	1 (11.1)

\*Also a treatment emergent AE causing permanent study drug discontinuation

## SDMT score

- At Month 12, the adjusted mean SDMT score changed minimally from Baseline for patients on siponimod (+0.26), whereas the placebo group had a 4.7-point worsening, with a difference between treatment groups of 4.9 (SE 2.6, p=0.07)

## Safety

- Siponimod was generally well tolerated
- Rates of AE, SAEs, and AEs leading to discontinuation were similar between treatment groups (**Table 2**)

## Conclusions

- There was a numeric relative reduction in CDP risk in siponimod-treated patients with active SPMS identifying as Hispanic, consistent with results observed in the overall active SPMS cohort in EXPAND
- The study was not designed to detect differences between subgroups, and the small sample size does not allow us to draw conclusions on the statistical significance of the results in the Hispanic subgroup.
- This brings into focus the challenges of minority under-representation in clinical trials

## References

1. Tremlett H, et al. *Mult Scler*. 2008;14:314–324.; 2. Scalfari A, et al. *J Neurol Neurosurg Psychiatry* 2014;85:67–75.; 3. Plantone D, et al. *CNS Drugs* 2016;30(6):517–526.; 4. Dumitrescu L, et al. *Expert Opin Pharmacother*. 2019;20:143–150.; 5. Gergely P, et al. *Br J Pharmacol*. 2012;167:1035–1047.; 6. Nuesslein-Hildesheim B, et al. *Mult Scler*. 2009;15:438.; 7. Kappos L, et al. *Lancet*. 2018;391:1263–1273.

## Abbreviations

AE adverse event; ANCOVA, analysis of covariance; CDP, confirmed disability; DMT, disease-modifying therapy; EDSS, expanded disability status scale; Gd<sup>+</sup>, gadolinium-enhancing; MS, multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis; SPMS, secondary progressive MS; SAE, serious adverse event; SD, standard deviation; SDMT, Symbol Digit Modalities Test.

## Disclosures

**SC:** speaking honoraria from Biogen, Bristol Myer Squibb, Novartis, Roche Genentech and Sanofi Genzyme; and serves on advisory boards or as a consultant to Biogen, EMD Serono, Novartis, and Sanofi Genzyme. Institutional research support (the Providence Brain and Spine Institute) was received from AbbVie, Adamas, Biogen, Novartis, Roche Genentech, Sage Bionetworks and Sanofi Genzyme. **LHH:** personal fees for speaking, consulting and advisory board activities from Biogen, Celgene, EMD Serono, Genentech, Genzyme and Novartis. **AB:** participated as a speaker in meetings sponsored by and received consulting fees and/or grant support from: Atara Biotherapeutics, Biogen Idec, Celgene/Receptos, Janssen/Actelion, MAPI, Medimmune, Merck/EMD Serono, Novartis, Roche/Genentech and Sanofi-Genzyme. **FDL:** personal compensation for consulting from AbbVie, Acorda Therapeutics, Actelion, Apitope, Atara Biotherapeutics, Bayer, Biogen, Brainstorm Cell Therapeutics, EMD Serono, Forward Pharma, Innate Immunotherapeutics, Mapi Pharma, MedDay Pharma, MedImmune, Novartis, Orion Biotechnology, Polpharma, Receptos/Celgene, Regeneron, Roche Genentech, Sanofi Genzyme, Teva Neuroscience and TG Therapeutics; and research support from Actelion, NMSS, Novartis Pharmaceuticals Corporation, Sanofi, Teva Neuroscience and Transparency Life Sciences. He has also received personal compensation as an editor for *Multiple Sclerosis and Related Disorders*. **PKC:** consulting fees from Accordant, Alexion, Bayer, Biogen, Celgene, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Mylan, Novartis, Serono and TG Therapeutics; and research grants from Actelion, Alkermes, Corrona LLD, Genentech/Roche, MedDay, NINDS, Novartis and PCORI. **RJF:** personal fees from Actelion, Biogen, Celgene, EMD Serono, Genentech, Immunic, Novartis and Teva; grants from Novartis; and other support from Biogen and Novartis (clinical trial contracts). **XM and GMC:** employees of Novartis Pharmaceuticals Corporation.

## Acknowledgments

The study was supported by Novartis Pharmaceuticals Corporation. Editorial support was provided by Juliel Espinosa, PhD, of Alphabet Health (New York, NY) and was funded by Novartis Pharmaceuticals Corporation. This poster was developed in accordance with Good Publication Practice (GPP3) guidelines. Authors had full control of the content and made the final decision on all aspects of this poster. This poster was previously presented at ECTRIMS 2021.

Poster Presentation at the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, 2021.

Copyright © 2021 Novartis Pharmaceuticals Corporation. All rights reserved.